AFT Pharmaceuticals Limited (NZX:AFT/ASX:AFP) (AFT) advises that the Annual Meeting of shareholders of AFT scheduled for 10.30am (NZ time) today will be adjourned to a time and date to be advised. This follows the Government’s announcement that the Auckland Region will move to COVID-19 alert level 3 today, which means that shareholders should stay home and refrain from attending the meeting.
Shareholders will be notified of the time and place of the adjourned meeting within the next 10 days.
AFT appreciates the support and understanding of shareholders with regard to this adjournment and apologises for any inconvenience. We believe this is the prudent response in the circumstances to protect the health and safety of all involved and to comply with the guidelines announced by the Government.
ENDS
– Released for and on behalf of AFT Pharmaceuticals Limited by Chief Financial Officer Malcolm Tubby
For more information:
Investors:
Dr Hartley Atkinson
Managing Director
AFT Pharmaceuticals
Tel: +64 9 488 0232
Media:
Richard Inder
The Project
Tel: +64 21 645 643
About Aft Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to the rest of the world.
